Exercise of Share Options and Director Dealings

Sareum Holdings PLC

02 November 2023

 

Sareum Holdings PLC

("Sareum" or the "Company")

Exercise of Share Options and Director Dealings

Cambridge, UK, 2 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that on 30 October 2023, Dr Tim Mitchell, Chief Executive Officer, and Dr John Reader, Chief Scientific Officer, each exercised options over 95,040 ordinary shares of 1.25 pence each ("New Ordinary Shares") in the Company (the "Options"), at an exercise price of 30 pence per New Ordinary Share, for an aggregate consideration of £57,024.

The Options were granted on 18 December 2013, under the Sareum Holdings plc Enterprise Management Incentives Option Agreement, and were due to lapse on 17 December 2023.

On exercise, Dr Mitchell and Dr Reader noted their intention to sell a proportion of such New Ordinary Shares in the market on receipt, partly in order to compensate for the cost and tax liabilities arising from the exercise. A further announcement will be released in due course disclosing such sales.

Following Admission (as defined below), Dr Mitchell's and Dr Reader's resultant interests in the Company will be as follows:

Director/ PDMR	Date of transaction	Number of shares purchased via Option exercise	Purchase price	Total shares held	Percentage of issued share capital
Tim Mitchell (1)	30 October 2023	95,040	30p	1,104,561	1.57%
John Reader (2)	30 October 2023	95,040	30p	1,127,537	1.60%

(1) - Included within Tim Mitchell's total holding are 200,000 Ordinary Shares held by his spouse.

(2) - Included withing John Reader's total holding are 66,666 Ordinary Shares held by his spouse. Please note this record corrects the typographical error in respect of John Reader's shareholding announced on 3 November 2021.

Admission

Application has been made to the London Stock Exchange for the 190,080 New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 November 2023.

Following Admission, the total number of Ordinary Shares in issue will be 70,261,878 and the total number of voting rights will therefore be 70,261,878. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact: 

Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations	01223 497700 [e-mail]
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm	020 7418 8900
Hybridan LLP (Joint Corporate Broker) Claire Noyce ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki	020 3764 2341 020 3709 5700

PDMR Notification Forms

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tim Mitchell
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	SAREUM HOLDINGS PLC
b)	LEI	213800PKERN2DY8FFM72
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1.25p each in the share capital of Sareum Holdings plc
	Identification code	ISIN for Ordinary Shares: GB00B02RFS12
b)	Nature of the Transaction	Exercise of Options to acquire ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 30p 95,040 acquired by way of an exercise of options
d)	Aggregated information -      Aggregated volume -      Price	Price(s) Volume(s) 30p 95,040 acquired by way of an exercise of options
e)	Date of the transaction	30 October 2023
f)	Place of the transaction	London Stock Exchange (AIM)

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Reader
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	SAREUM HOLDINGS PLC
b)	LEI	213800PKERN2DY8FFM72
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 0.025p each in the share capital of Sareum Holdings plc
	Identification code	ISIN for Ordinary Shares: GB00B02RFS12
b)	Nature of the Transaction	Exercise of Options to acquire ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 30p 95,040 acquired by way of an exercise of options
d)	Aggregated information -      Aggregated volume -      Price	Price(s) Volume(s) 30p 95,040 acquired by way of an exercise of options
e)	Date of the transaction	30 October 2023
f)	Place of the transaction	London Stock Exchange (AIM)

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

 

END